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Abstract
Background: Placebo interventions can have meaningful effects for patients. However, little is
known about the circumstances of their use in clinical practice. We aimed to investigate to what
extent and in which way Swiss primary care providers use placebo interventions. Furthermore we
explored their ideas about the ethical and legal issues involved.
Methods: 599 questionnaires were sent to general practitioners (GPs) and paediatricians in
private practice in the Canton of Zurich in Switzerland. To allow for subgroup analysis GPs in
urban, suburban, and rural areas as well as paediatricians were selected in an even ratio.
Results: 233 questionnaires were completed (response rate 47%). 28% of participants reported
that they never used placebo interventions. More participants used impure placebos therapeutically
than pure placebos (57% versus 17%, McNemar's χ2 = 78, p < 0.001). There is not one clear main
reason for placebo prescription. Placebo use was communicated to patients mostly as being "a drug
or a therapy" (64%). The most frequently chosen ethical premise was that they "can be used as long
as the physician and the patient work together in partnership" (60% for pure and 75% for impure
placebos, McNemar's χ2 = 12, p < 0.001). A considerable number of participants (11–38%) were
indecisive about statements regarding the ethical and legal legitimacy of using placebos.
Conclusion: The data obtained from Swiss primary care providers reflect a broad variety of views
about placebo interventions as well as a widespread uncertainty regarding their legitimacy. Primary
care providers seem to preferentially use impure as compared to pure placebos in their daily
practice. An intense debate is required on appropriate standards regarding the clinical use of
placebo interventions among medical professionals.
Background
Numerous studies demonstrate that placebo interven-
tions can have an influence on outcomes and may benefit
the patient [1-5]. On the other hand, the evidence that
placebo interventions can significantly alter clinical out-
comes has been questioned, and some authors have cau-
tioned against their possible negative effects [6-8]. This
unsettled dispute about the appropriate role of placebo
interventions in clinical settings is reflected by the regula-
tory situation: While the use of placebos in research is
extensively regulated by national and international guide-
lines, their use in clinical practice often occurs in a legal
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and ethical gray zone. In this context of normative uncer-
tainty the standards that primary care providers develop
to guide their own practice are of particular interest.
Various definitions of the term "placebo" have been sug-
gested in the literature. We usually prefer the term "pla-
cebo intervention" because it is not only the concrete
placebo "vehicle" (i.e. the drug or the procedure) that can
influence outcomes but rather all context factors includ-
ing the perceptions and expectations of the patients. We
define a placebo intervention as an intervention which
has no direct pharmacological, biochemical or physical
mechanism of action according to the current standard of
knowledge. It can take the form of a placebo medication
or of a diagnostic or therapeutic sham procedure.
We chose to use the distinction between "pure" and
"impure" placebos, which is well established in the litera-
ture [6,8-10]. "Pure placebos" refer to inert substances or
methods, whereas "impure placebos" include substances
or methods which do have a known pharmacological or
physical activity but which cannot be expected to have any
direct therapeutic effects for the respective disease and in
the chosen dosage.
We decided to use this distinction although it cannot be
applied to all placebo interventions in a clear cut way – for
instance, diagnostic placebo interventions cannot easily
be attributed to either category. Our hypothesis was that
clinical use and the moral reasoning accompanying it
would be quite different for both categories so that the
distinction would help us to gain a more nuanced under-
standing of the ways physicians think about and use pla-
cebo interventions.
In the past twenty years, six surveys have been published
that address the attitudes and habits of physicians with
regard to the use of placebo interventions [10-15]. The
reported percentage of physicians using placebo interven-
tions in clinical practice ranged from 41% to 99%
depending on their specialty and, more importantly, the
context of the survey question. In a Swedish study for
instance, the use of antibiotics for viral infections was pre-
sented to the physicians as a placebo treatment. Thus the
physicians were focused on impure placebos when they
were asked about their prescribing habits regarding pla-
cebo treatment. This may have led to the high percentage
of positive responses (99%) [15]. There are publications
of surveys which do not even mention if a certain defini-
tion of the term "placebo" was given to participants
[13,15]. Defining the term is highly important, however,
because many definitions and conceptions of placebo
exist in the literature and therefore different conceptions
of placebos among survey participants will influence their
statements.
Until now no survey has explored whether physicians
handle pure and impure placebos differently, and the rea-
sons for rejecting or accepting the use of placebo interven-
tions have only been touched upon. To our knowledge
ours is the first survey which systematically studies the
potential differences in the use of pure as compared with
impure placebos. The overall goal of our study was to
determine to what extent and in which ways Swiss pri-
mary care providers utilise placebo interventions. Further-
more we explored their ideas about the ethical and legal
issues involved.
Methods
Participants
In Switzerland, primary care is mainly provided by gen-
eral practitioners (GPs) and paediatricians, so we chose to
send our questionnaire to those two groups. Postal
addresses were received from a register of the medical
association of the Canton of Zurich and additionally from
the database http://www.twixtel.ch. A total of 149
addresses of paediatricians and 1518 of general practi-
tioners in private practice were available. We stratified the
addresses of the GPs according to their location and
selected randomly 150 GPs from urban areas, 150 GPs
from suburban areas, and 150 GPs from rural areas. The
groups were coded by using different colours for the ques-
tionnaires. The group size was determined by the number
of available paediatricians. Overall we included 599 pri-
mary care providers in our survey.
The Research Ethics Committee of the Canton of Zurich
stated that the study did not require ethical review.
Questionnaire
The questionnaire consisted of 14 multi-unit questions on
four pages and can be downloaded from
http:www.ethik.uzh.ch/ibme/team/margritfaessler/
Fragebo gen.pdf in its original German version. For an
English version see the Additional file 1. Reponses to
questions no. 11–14, which focus on participants' ideas
about the mode of action of placebo interventions and
their relationship to complementary medicine, will be
reported and discussed elsewhere.
On the top of the questionnaire, we placed our definitions
of "placebo intervention", "pure", and "impure placebos"
(Table 1).
Subsequently the questionnaire pointed out that the ques-
tions referred only to the use of placebo interventions in
clinical practice, not to placebos given as controls in clin-
ical trials.
In addition to demographic data we focused on the fol-
lowing questions about the use of placebo interventions:BMC Health Services Research 2009, 9:144 http://www.biomedcentral.com/1472-6963/9/144
Page 3 of 9
(page number not for citation purposes)
Which placebo interventions study participants use,
whether they use placebo interventions at all, for which
motives, how often, what they communicate to the
patient, their attitude towards placebos, and the estimated
disappointment of patients were they to discover that they
had unknowingly received a placebo. Responses required
the distinction between pure and impure placebos.
In three consecutive pilot studies, we pretested our ques-
tionnaire with a total of 27 GPs or paediatricians and
revised some wording. The survey was conducted between
December 2007 and March 2008. The questionnaires
were sent out by mail with a letter explaining the aim of
the survey and the anonymous data processing. Two
reminders were sent out. Codes on the returning enve-
lopes were used to identify participants who did not need
a reminder. On return, the envelope was separated from
the questionnaire for anonymous data processing.
Statistical analysis
We processed our data analysis using SPSS version 16.
Every item was checked for differences caused by the fol-
lowing variables: location area (urban vs.
suburban vs. rural), paediatricians vs. GPs, gender and age
group (<50 vs. ≥ 50 yrs). In order to reduce multiple sta-
tistical testing and to obtain only relevant group differ-
ences, we first checked for group differences amounting to
over 15%, and applied χ2-testing only to items with group
differences above the cut off.
Differences in ordinal scale variables were assessed by
Wilcoxon's rank sum test (e.g. presumed disappointment
after knowledge of having received pure as compared to
impure placebo), while binomial variables were com-
pared with McNemar's χ2 test (e.g. consent to pure vs.
impure placebo treatment). Statistical significance level
was 0.05 with a two tailed hypothesis. Values are given as
frequencies or mean and SD.
Results
The final version of the questionnaire was sent out to 599
Swiss primary care providers who practise in medical
offices. Two of them were returned because their
addresses were unknown, and 15 respondents declared
not to be a GP or paediatrician or not to have a private
practice. This left a sample of 582.
The questionnaires were collected by MG who managed
the reminders. For the extraction of data the question-
naires were sent from MG to MF as soon as a significant
amount had been received. 83 of these, mostly filled ques-
tionnaires got lost by the mailing company and could not
be retrieved. To calculate the response rate we subtracted
the 83 lost questionnaires from the original sample of 582
and set 499 as 100%, which leads to a 47% response rate
for the available 233 completed questionnaires.
Demographics
The characteristics of the respondents are shown in Table
2. The return rate of the primary care providers in urban
areas was lower than in suburban or rural areas. The pro-
portion of female respondents (29%) corresponds to the
percentage of women in private practice in primary care in
the Canton of Zurich (22%) [16].
Use of placebo interventions
66 of the 233 (28%) participants reported that they did
not make any clinical use whatsoever of interventions
they considered a placebo. To answer the question
whether the frequency of therapeutic use of pure and
impure placebos was different we took the data from par-
ticipants who answered both question 5 and 6 ("If you use
pure/impure placebos therapeutically – what do you tell
the patient?"), i.e. 203 of the 233 participants. Signifi-
cantly more participants used impure placebos (116 of
203) than pure placebos (34 of 203) for therapeutic pur-
poses (57% versus 17%, McNemar's χ2 = 78, p < 0.001).
93% of those who do use pure placebos used them once a
month or less, 2% weekly, and 5% daily.
Table 3 shows how often different placebo interventions
are utilised by the participants. In the questionnaire
respondents could indicate their view on the respective
intervention being a placebo intervention or not (last two
columns). The most frequently mentioned placebo inter-
Table 1: Definition of Placebo Intervention, Pure, and Impure Placebos
Placebo intervention We define a placebo intervention as a diagnostic or therapeutic sham intervention or as an intervention with substances 
or physical methods which have no direct pharmacological, biochemical or physical mechanism of action according to the 
current standard of knowledge. The term includes a considerable variety of interventions, thus not only the 
administration of lactose tablets or isotonic saline solution.
Pure placebos Are inert substances or methods such as sugar pills or isotonic saline solution.
Impure placebos Refer to substances or methods which have a known pharmacological or physical activity but which cannot be expected 
to have any direct therapeutic effects for the respective disease and in the chosen dosage, e.g. vitamin infusions for 
cancer or peppermint pills for pharyngitis.BMC Health Services Research 2009, 9:144 http://www.biomedcentral.com/1472-6963/9/144
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ventions were diagnostic procedures in the form of non-
essential physical examinations of the patient (89%), fol-
lowed by positive suggestions (81%). Only 7% of the par-
ticipants had provided sugar pills, 10% reported
injections with saline solution. Again we did not find any
group differences.
Motives for the use of placebo interventions
Table 4 shows the motives for using placebo interventions
among the participants using placebos for diagnostic or
therapeutic reasons (n = 167). Considering both, the
group who uses just impure placebos and the group who
uses both pure and impure placebos together, the most
frequently chosen motives were "to gain therapeutic
advantage through the placebo effect" (69%), "to offer a
treatment to patients whose complaints and test results
are not attributable to a certain disease" (64%), and "to
conform with the requests of the patient" (63%).
The two least frequently chosen motives overall were "to
test whether the pain is psychogenic or organic" (21%)
and "to avoid drug addiction" (30%). All items were cho-
sen more frequently by those who stated to use impure
placebos only, with the exception of using placebos as a
test to distinguish "psychogenic" from "organic pain". The
participants had the possibility to note additional motives
that guided their use of placebo interventions but only 4
of the respondents made use of this option.
When looking for interaction with our tested class varia-
bles, we found the following group differences: Fewer pae-
diatricians than GPs used only impure placebos to treat
Table 2: Sample characteristics
Category N Count (percentage) or mean ± SD
Group of physicians 233
Paediatricians 67 (29%)
GPs in urban areas 41 (18%)
GPs in suburban areas 55 (24%)
GPs in rural areas 70 (30%)
Gender 227
Women 65 (29%)
Men 162 (71%)
Age (years) 228 52 + 9
Days per week working in private practice 197 4.1 + 1.2
Patients seen per day 224
<15 35 (16%)
15–30 150 (67%)
>30 39 (17%)
Table 3: Use of placebo interventions and the question whether the participants view the respective intervention as placebo 
intervention
N . I have already used . I have not used so far N ... is not a placebo intervention.
Positive suggestions 180 146 (81%) 34 (19%) 197 62 (32%)
Simple ointments and/or bandages for 
contusions without visible skin damages
181 137 (76%) 44 (24%) 197 52 (27%)
„Sugar pills” 196 14 (7%) 182 (93%) 197 3 (2%)
Injections with saline solution 198 20 (10%) 178 (90%) 199 4 (2%)
Therapies without pharmacological or 
physical efficacy for the patient's 
conditions 
(e.g. vitamins or antibiotics without 
approved indication)
195 119 (61%) 76 (39%) 196 12 (6%)
Diagnostic practices:
￿ non-essential physical examinations of 
the patient
193 171 (89%) 22 (11%) 200 38 (19%)
￿ non-essential technical examinations 
of the patient without relevant risks 
(e.g. ultrasound, MRI)
195 134 (69%) 61 (31%) 197 24 (12%)
￿ non-essential technical examinations 
of the patient with relevant risks 
(e.g. computed tomography)
192 59 (31)% 133 (69%) 195 21 (11%)BMC Health Services Research 2009, 9:144 http://www.biomedcentral.com/1472-6963/9/144
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patients with unspecific complaints (23 vs. 40%, p <
0.05). Also fewer paediatricians than GPs used only
impure placebos in difficult patients (13 vs. 33%, p <
0.01).
Communication about placebo use
When using pure or impure placebos, most participants
reported telling their patients that they received a drug or
a therapy (see Table 5). No one reported that he or she
told the patients that the intervention was a placebo. Rel-
atively few referred to the placebo as "a medicine with no
specific effect" (11% for pure, 27% for impure placebo).
Ethical and legal issues of using placebo interventions
Study participants were asked if they agreed or disagreed
with six statements about the use of pure or impure place-
bos in medical practice (Table 6). Their "I am uncertain"
answers ranged from 11 to 38%, with the statement "The
use of placebos must be rejected in principle because there
are legal concerns" provoking most uncertainty (38% for
the use of pure placebos, 30% for impure placebos). The
most frequently confirmed statement for both pure and
impure placebos was "The use of placebos can be used as
long as the physician and the patient work together in
partnership" (60% for pure vs. 75% for impure placebo).
For all six questions, there was more agreement with the
statements regarding the use of impure placebos than of
pure placebos (Wilcoxon's rank sum test, z = 8.2, p <
0.001).
As a group difference we found that paediatricians less
often than GPs rejected the use of pure placebos for its
implying the deception of patients (43 vs. 60%, χ2 = 4.7,
p = 0.03).
Table 4: Motives for the use of placebo interventions among the 167 users
N I use pure and impure placebos* I use only impure placebos* I use no placebos at all
To conform with the requests of the 
patient
159 17 (11%) 83 (52%) 59 (37%)
To gain a therapeutic advantage through 
the placebo effect
157 31 (20%) 77 (49%) 49 (31%)
To still be able to offer a treatment option 
to a patient with an „incurable” disease
154 12 (8%) 55 (36%) 87 (56%)
To offer a treatment in situations in which 
standard treatments may strongly burden 
patients with side effects or are 
contraindicated
158 13 (8%) 46 (29%) 99 (63%)
To offer a treatment to patients whose 
complaints and test results are not 
attributable to a certain disease 
(unspecific complaints)
162 24 (15%) 80 (49%) 58 (36%)
To offer treatment to difficult patients with 
psychological peculiarities, i.e. constant 
unwarranted complaints
156 19 (12%) 61 (39%) 76 (49%)
To test whether the pain is psychogenic or 
organic
154 20 (13%) 12 (8%) 122 (79%)
To avoid drug addiction 155 12 (8%) 35 (23%) 108 (70%)
*Definitions see Table 1.
The total percentage may not equal 100 due to rounding.
Table 5: What participants tell their patients when using placebos for therapeutic purposes
Use of pure placebos therapeutically 
(n = 222)
Use of impure placebos therapeutically 
(n = 208)
User: 35 119*
I tell them
... this is a drug/a therapy. 22 (63%) 77 (65%)*
... this is a placebo. 0 (0%) 0 (0%)
... this is a medicine with no specific effect. 4 (11%) 32 (27%)*
I say nothing. 9 (26%) 10 (8%)
Nonuser:
I never use placebos for therapeutic purposes. 187 89*
Only one answer allowed, *p < 0.001 vs. pure placebo by McNemar's χ2 test.
Percentages refer to the number of users.BMC Health Services Research 2009, 9:144 http://www.biomedcentral.com/1472-6963/9/144
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Presumed patient reaction to being informed about 
placebo use
A considerable percentage of participants presumed that
many of their patients would be disappointed if they came
to know that they had been intentionally treated with a
placebo: This worry was more pronounced regarding the
use of pure placebos (55%) than in the case of an impure
placebo (22%) (p < 0.001 by Wilcoxon's rank sum test)
(Table 7). Less paediatricians than GPs were worried
about their patient's disappointment when a pure placebo
had been used (49 vs. 68%, χ2 = 12.4, p < 0.01).
Discussion
Our survey gives a detailed picture of the use of placebo
interventions in clinical practice and illustrates the atti-
tudes of primary care providers. 72% of the 233 partici-
pants use placebo interventions in certain situations.
Overall, far more participants make therapeutic use of
impure placebos than of pure placebos (57% vs. 17%).
This corresponds to results of a recently published US sur-
vey in which 41% of the physicians recommended over
the counter analgesics as placebo treatment and 2–3% rec-
ommended inert substances within the past year [10].
Within our sample of primary care providers we could not
detect any differences in the frequency of using pure pla-
cebos regarding their medical specialty (GP or paediatri-
cian) or the localisation of their practice.
The most frequently used justification for the use of place-
bos in medical practice was that it can be used as long as
the physician and the patient work together in partner-
ship: 60% of all participants agreed with this statement
with regard to the use of pure placebos, and 75% agreed
with regard to impure placebos. This emphasis on a ther-
apeutic partnership of patients and physicians contrasts,
however, with participants' concern about their patients'
disappointment if they found out they were intentionally
treated with a placebo. Possibly physicians would want to
find ways to use placebos in a non-deceptive manner that
is in accord with a partnership model of the physician-
patient-relationship, but have not yet found a suitable
way of realizing this.
The most frequently endorsed argument against the use of
placebos concerned the deception it implied vis-à-vis the
patient: 45% of the participants agreed with this argument
regarding pure placebos, and 24% regarding impure pla-
cebos (p < 0.001 for pure vs. impure placebos). Other sur-
veys asked somewhat different questions. An Israeli survey
reported that 5% of participants thought that the use of
Table 6: Statements regarding the ethical and legal legitimacy of placebo use
Use of pure placebos Use of impure placebos
N I agree I am un-certain I disagree N I agree I am un-certain I disagree p value*
The use of placebos
￿ must be rejected in principle because it is 
ineffective.
220 58
(26%)
37
(17%)
125
(57%)
220 41
(19%)
26
(12%)
153
(70%)
p < 0.05
￿ must be rejected in principle because it 
implies deceiving the patient.
223 101
(45%)
39
(17%)
83
(37%)
221 52
(24%)
39
(18%)
130
(59%)
p < 0.001
￿ must be rejected in principle because of 
legal concerns.
220 43
(20%)
84
(38%)
93
(42%)
221 30
(14%)
67
(30%)
124
(56%)
n.s.
￿ can be used as long as physician and 
patient work together in partnership.
220 132
(60%)
35
(16%)
53
(24%)
221 166
(75%)
25
(11%)
30
(14%)
p < 0.001
￿ is acceptable for the benefit of the patient 
and for minimizing harm to the patient.
219 120
(55%)
43
(20%)
56
(26%)
221 158
(71%)
24
(11%)
39
(18%)
p < 0.01
￿ is for me a traditional component of 
medical practice.
219 37
(17%)
25
(11%)
157
(72%)
217 91
(42%)
26
(12%)
100
(46%)
p < 0.001
Multiple answers allowed. * Significance testing by use of McNemar's Chisquare test, pure vs. impure placebo ("I am uncertain"-answers were 
excluded from analysis).
The total percentage may not equal 100 due to rounding.
Table 7: Presumed disappointment of patients if they learned that they had been intentionally treated with a pure or impure placebo*
Use of pure placebo (n = 223) Use of impure placebo (n = 225)
Yes, many of my patients 123 (55%) 49 (22%)
Yes, some of my patients 47 (21%) 53 (24%)
Mostly no 27 (12%) 103 (46%)
I do not know. 26 (12%) 20 (9%)
* Counts for pure vs. impure placebo were significantly different, Wilcoxon's, z = 8.7, p < 0.001.BMC Health Services Research 2009, 9:144 http://www.biomedcentral.com/1472-6963/9/144
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placebos should be categorically prohibited [13]. Surveys
from the USA obtained 7 to 12% for this item [10,12], and
a Danish survey found that placebo interventions were
ethically unacceptable to 40% of study participants [11].
As the placebo definitions that the studies used differ, the
possibilities to compare these data are limited.
Why is it useful to distinguish pure from impure place-
bos? The use of pure or inert placebos has met with scep-
ticism by ethicists mainly because it presumably implies
the deception of the patient, representing an outdated,
unduly paternalistic physician-patient-relationship
[17,18]. By contrast, the use of impure or active placebos
seems easier to justify by the (to some extent sophistic)
argument that, though not probable, these placebos could
have some pharmacological or physical activity that has a
positive effect on the health of the patient but is difficult
to verify. One could also argue that interventions with
impure placebos may have greater placebo effects than
interventions with pure placebos because the theory and
framework of the impure placebo intervention can lead to
positive expectations or conditioned responses in
patients. An intervention that is accompanied by positive
information in the lay press can be expected to work better
than a nameless pill without package insert. This assump-
tion is in accordance with recent data showing that the use
of expensive placebo pills reduces pain better than the use
of cheaper ones [19]. On the other side it should not be
neglected that impure placebos can cause harmful side
effects, which incidentally can be severe, e.g. an allergic
reaction to an antibiotic given for a viral infection.
In our sample, the use of placebos, be they pure or
impure, was usually communicated to the patient as a
"medication" or "therapy". It is unknown whether telling
patients explicitly the nature of placebo treatment com-
promises placebo effects or not. The existing empirical
data that deny an influence are weak [20]. It is possible
that physicians underestimate the effectiveness of placebo
interventions in adequately informed patients as well as
the openness of the latter to try and take advantage of the
power of the placebo. But this would need to be explored
further in studies focusing on the patient's perspective.
Still, physicians' information about medical interventions
frequently include a grain of interpretation or untruthful-
ness – be it that the prospect of cure is somewhat exagger-
ated or the likelihood of adverse effects a bit downplayed.
Determining what degree of such paternalistic, albeit
benevolent, manipulation of medical information is
appropriate for the individual patient-physician-relation-
ship is part of a physician's responsibilities. Often there is
an implicit mutual agreement and trust that the doctor
will make the right choice of treatment.
A remarkable finding is the uncertainty among partici-
pants as regards the ethical and legal status of placebos as
well as their effectiveness. 11 to 38% were uncertain how
to appraise the respective statement presented to them in
the questionnaire. Another cue revealing the uncertain-
ness of participants is that we found only limited agree-
ment on the motives to use placebo interventions. 72% of
the participants administer placebo interventions to their
patients in certain circumstances. There is less agreement
among those who use placebo interventions for certain
motives than might be expected. About two-thirds of
those who use placebo interventions agreed with the three
motives "to gain a therapeutic advantage of a placebo
effect", "to offer a treatment to patients whose complaints
and test results are not attributable to a certain disease",
and "to conform with the requests of the patient".
Other authors found still less consensus regarding the
motives or circumstances among placebo users. Sherman
and Hickner reported that for the respondents who used
placebos the most common motive was "to calm the
patient" and "as supplemental treatment" (both 18%)
[12]. In the survey of Nitzan and Lichtenberg the most fre-
quently reported circumstance for placebo use was "after
'unjustified' demand for medication" (48%) [13]. Berger
found 48% of those who used as well as those who usu-
ally did not use placebos were likely to use a placebo
when they suspected factitious pain [14]. Only Hróbjarts-
son and Norup referred to a more stable consensus: 70%
of the general practitioners who used placebo interven-
tions agreed about the motive "following the wish of the
patient and avoiding a conflict with the patient" [11]. All
in all, the use of placebo interventions in general practice
does not seem to follow clear patterns, in particular not
from an international, cross-cultural perspective. There is
not one main clear reason for placebo use.
The reason for the uncertainness of participants may well
be due, at least in part, to their unfamiliarity with recent
or even well-established findings of placebo research, e.g.
as being reviewed by Price et al. [21]. Another reason may
be that there is no commonly accepted consensus in the
literature on how to use placebo interventions in clinical
practice. We found neither (Swiss) national nor interna-
tional policies which would help answering the question
when and how to use placebo interventions in practice,
although individual authors have made suggestions to
that effect [22]. The ubiquitous requirement of informed
consent is not fine-grained enough to provide much guid-
ance when it comes to the more subtle issues of using pla-
cebo interventions. For example, there is no guidance on
how to explain the mechanism of action of a proposed
placebo intervention to the patient. Finding the right bal-
ance between putting the patient off by being too explicit
about the placebo nature of the intervention and by being
so vague as to be almost deceptive is a challenging task
that might benefit from well-tailored recommendations.BMC Health Services Research 2009, 9:144 http://www.biomedcentral.com/1472-6963/9/144
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A reassuring finding was that a vast majority of the Swiss
primary care providers (85%) denied the factual use of
placebos to test whether pain is psychogenic or organic.
There is no evidence in the literature to corroborate the
utility or plausibility of this test [14,23,24]. Ignoring the
slightly different wording of questions in surveys address-
ing the usefulness of placebos to distinguish symptoms
that have a psychogenic versus an organic origin, there is
a high variability of adherence to this misleading theory
among physicians: 19% [25], 20% [12], 53% [24], 68%
[14] when asked for hypothetical use and 4% [12], 18%
[11], 19% [13], 48% [14] when asked for the factual use.
Some limitations of our study need to be acknowledged.
To illuminate many aspects of the use of placebo interven-
tions in clinical practice, we developed a rather extensive
questionnaire which may have cut the response rate. Non-
respondents and missing data may have led to possible
biases. Other surveys about placebo use also had response
rates under 60% [10,12,23,26], which may well have its
reasons in the somewhat delicate nature of the topic on
the one hand and the high workloads of practicing physi-
cians on the other, reducing the readiness to participate in
research [27]. A formal testing of differences in age and
gender for respondents and non-respondents cannot be
presented for our study because we did not collect these
data from non-respondents. Therefore we can not say
whether the low response rate of our survey introduced
marked bias to our data. However, the age and gender of
the respondents do fit well with the data of Zurich Medi-
cal Association.
Despite our clearly stated definition of placebo interven-
tions, the answers of the participants may have been influ-
enced by different concepts about placebo interventions.
For example, primary care providers who practice psycho-
therapy may have been confused our definition not
explicitly excluding psychotherapy. Placebo effects can
also be conceived as psychologically mediated effects and
therefore it seemed inadequate and artificial to us to draw
a sharp, explicit line between the effects of psychotherapy
and placebo effects for the purposes of our definition.
Still, had we explicitly included or excluded psychother-
apy in our definition some participants might have
replied differently to the question whether they do or do
not apply placebo interventions to their patients.
The reported prevalence of use of pure placebos depended
on the subjective criteria used to separate pure and impure
placebos. For example, participants could consider
homoeopathic remedies as pure placebos or not. Also, we
did not ask for the frequency of the use of impure place-
bos because we assumed that answering this question
would be very difficult as their use was too prevalent to be
reliably quantified by an estimation. [15].
In clinical practice, physicians are often confronted with
situations in which either a scientifically proven therapy is
not known, may have unacceptable side effects, or in
which the patient's complaints cannot be interpreted
within the framework of a well-defined diagnosis. In such
cases the physician could wait and see whether the
"unspecific" symptoms may disappear without any inter-
vention. But many patients do not get better by mere wait-
ing, and their subjectively perceived illness remains
considerable. Why not harness "the sometimes powerful
beneficial effect of a placebo" [28]? The ambivalence and
uncertainty of physicians who do not want to fall into the
trap of arrogant and inappropriate paternalism is quite
understandable. There may be ways, however, of getting
the "power of the placebo" to work without losing the
patient as a partner. Exploring those possibilities and
defining suitable limits to the clinical use of placebo inter-
ventions seem to be an important next step [29].
Conclusion
The data obtained from Swiss primary care providers
reflect a broad variety of views about placebo interven-
tions as well as a widespread uncertainty regarding their
legitimacy. Primary care providers seem to preferentially
use impure as compared to pure placebos in their daily
practice.
An intense debate is required on appropriate standards on
the clinical use of placebo interventions among medical
professionals that reaches out to the perspective of those
whose interests and wellbeing are the ultimate goal of all
medical interventions: the patients.
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